Technical Data
Vimentin (FLJ36605, VIM) (FITC)
The binding region of this antibody has been characterized by Bohn et al. (1992). According to these authors, the epitope has been localized on the alphahelical part of vimentin (rod domain coil 2). Due to an aa substitution at position of aa353 in murine vimentin (that could explain for the weak crossreaction of the antibody with murine vimentin) they were able to narrow down the binding region around position 353. These findings were confirmed by truncation mutagenesis experiments using human vimentin (Rogers et al., 1995).

Suitable for use in Western Blot, FLISA, Immunofluorescence microscopy and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Immunohistochemistry (frozen and paraffin-embedded tissue and cytological material): 1:10 with PBS, pH 7.4; Incubation Time 1 hr at RT; extended with paraffin. Protease pretreatment is required prior to antibody application.
Optimal dilution determined by the researcher.

Positive Controls:
Cultured RD cells, glioma cells, fibroblasts (SV-80), MDCK. Tumors specifically detected: sarcoma (including myosarcoma), lymphoma, melanoma.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. FITC conjugates are sensitive to light.

MabIgG2a5F310Affinity Purified
250ul-20CBlue IceBovineMouse
As reported
Vimentin (purified from bovine lens).
Purified by Protein A affinity chromatography.
Supplied as a liquid. Labeled with FITC.
Recognizes the intermediate filament protein of bovine vimentin at 57kD, which is present in all cells of mesenchymal origin. Species Crossreactivity: human, monkey, canine, chicken, amphibia (e.g. Xenopus laevis). Weaker mouse cross-reaction. Reactivities on Cultured Cells: RD Cells, glioma cells, fibroblasts (SV-80), MDCK.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Heid HW, et al., Differentiation 37, 137-157, 1988. 2. Hermann H, et al., Differentiation 36, 234-254 (1987 Kasper M, et al., Histochemistry 93, 93-103, 1989. 3. Kasper M, et al., Differentiation 40, 207-214, 1989. 4. Moll I et al., Arch Dermatol Res 283, 300-309, 1991. 5. Gmi H, et al., Neuron, 14, 29-41, 1995. 6. Demirkesen C, et al., J Cutan Pathol 22: 518-535, 1995. 7. Hermann H, et al., J Mol Biol 234: 99-113, 1993. 8. Rogers KR, et al., Eur J Cell Biol 66: 136-150, 1995. 9. Bohn W, et al., Exp Cell Res 201: 1-7, 1992. 10. Hermann H, et al., J Mol Biol 223: 637-650, 1992. 11. Koeser J, et al., Exp Cell Res 285, 114-130, 2003 .